If you have been reading about Dihexa and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-09. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
GnRH antagonists (receptor blockers) such as degarelix are synthetic peptide derivatives of the natural GnRH decapeptide – a hormone that is made by neurons in the hypothalamus. GnRH antagonists compete with natural GnRH for binding to GnRH receptors in the pituitary gland. This reversible binding blocks the release of LH and FSH from the pituitary. The reduction in LH subsequently leads to a rapid and sustained suppression of testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer. This in turn results in a reduction in prostate-specific antigen (PSA) levels in the patient's blood. Measuring PSA levels helps to monitor how patients with prostate cancer are responding to treatment. Unlike GnRH agonists, which cause an initial stimulation of the hypothalamic-pituitary-gonadal axis (HPGA), leading to a surge in testosterone levels, and under certain circumstances, a flare-up of the tumour, GnRH antagonists do not cause a surge in testosterone or clinical flare. Clinical flare is a phenomenon that occurs in patients with advanced disease, which can precipitate a range of clinical symptoms such as bone pain, urethral obstruction, and spinal cord compression. Drug agencies have issued boxed warnings regarding this phenomenon in the prescribing information for GnRH agonists. As testosterone surge does not occur with GnRH antagonists, there is no need for patients to receive an antiandrogen as flare protection during prostate cancer treatment.
Akuammine (vincamajoridine) is an indole alkaloid. It is the most abundant alkaloid found in the seeds from the tree Picralima nitida, commonly known as akuamma, comprising 0.56% of the dried powder. It has also been isolated from Vinca major. Akuammine is structurally related to yohimbine, mitragynine and more distantly voacangine, all of which are alkaloid plant products.
Watson, Crick, Wilkins and Franklin all worked in MRC laboratories. Crick and Watson felt that they had benefited from collaborating with Wilkins. They offered him a co-authorship on the article that first described the double helix structure of DNA. Wilkins turned down the offer, a fact that may have led to the terse character of the acknowledgement of experimental work done at King's College in the eventual published paper. Rather than make any of the DNA researchers at King's College co-authors on the Watson and Crick double helix article, the solution that was arrived at was to publish two additional papers from King's College along with the helix paper. Brenda Maddox suggests that because of the importance of her experimental results in Watson and Crick's model building and theoretical analysis, Franklin should have had her name on the original Watson and Crick paper in Nature. Franklin and Gosling submitted their own joint "second" paper to Nature at the same time as Wilkins, Stokes, and Wilson submitted theirs (i.e. the "third" paper on DNA). Watson's portrayal of Franklin in The Double Helix was negative and gave the appearance that she was Wilkins' assistant and was unable to interpret her own DNA data. However, according to Nathaniel C. Comfort, a historian of medicine at Johns Hopkins University, Franklin's colleague Aaron Klug believed that Franklin "..was 'two steps away' from the double helix. After completing an analysis of her lab notebook, Klug stated that she surely would have had it.
Sources: en.wikipedia.org
Both the PP and the PSOE refused to participate in the proposed dialogue under those conditions, which meant "the demise of the Ajuria Enea Mesa, which would never reconvene again." After the failure of the "Ardanza Plan", the PNV, EA and HB ─ and also the United Left of the Basque Country ─ signed the Treaty of Estella on September 12, 1998, and four days later ETA announced the indefinite cessation of violence. Thus, 1999 was the first year since 1971 without any deaths from ETA attacks, although the street violence of the kale borroka did not disappear. During the truce, the PP government even made contacts with the ETA leadership but maintained the idea expressed by Interior Minister Jaime Mayor Oreja that it was a "trap truce", that is, that ETA had proclaimed the cessation of violence only to reorganize itself after the hard police blows it had received. In November 1999, ETA announced the breaking of the truce due to the lack of progress in the Basque "process of national construction" and in January 2000 it perpetrated a new attack. Another of the "reasons" for ending the truce had been that neither the 1998 Basque Parliament elections nor the municipal and foral elections of June 1999 had resulted in an overwhelming victory of the parties supporting the "Lizarra Pact" against the "constitutionalist" parties.
=== Osteoarthritis === Tentative evidence supports the use of PRP in osteoarthritis of the knee. A 2019 meta-analysis found that PRP might be more effective in reducing pain and improving function than hyaluronic acid in knee arthritis. This therapeutic effect is not only considered to be dependent on the concentration of growth factors but also on the presence of plasma clotting factors which can help to regulate inflammation and joint tissue regeneration.
==== Starch-based adhesives ==== Starch pastes can be applied with cold lining techniques, which are preferred over heat and pressure-based methods when dealing with degraded or fragile fibers. Carbohydrate-based adhesives are often made from wheat starch and arrowroot/sodium alginate. They are frequently used with Japanese scrolls and panels due to material compatibility and coherence with traditional techniques.
The main symptom of osteoarthritis is pain, causing loss of ability and often stiffness. The pain is typically made worse by prolonged activity and relieved by rest. Stiffness is most common in the morning, and typically lasts less than thirty minutes after beginning daily activities, but may return after periods of inactivity (such as prolonged sitting). Pain with ascending/descending stairs or getting in or out of a car or the bath is associated with osteoarthritis of the patellofemoral joint (the joint behind the kneecap), as this joint is stressed with knee flexion. Osteoarthritis can cause a crackling noise (called "crepitus") when the affected joint is moved, especially the shoulder and knee joints. A person may also complain of joint locking and joint instability. These symptoms would affect their daily activities due to pain and stiffness. Some people report increased pain associated with cold temperature, high humidity, or a drop in barometric pressure, but studies have had mixed results. Osteoarthritis commonly affects the hands, feet, spine, and the large weight-bearing joints, such as the hips and knees, although any joint in the body can be affected. As osteoarthritis progresses, movement patterns (such as gait), are typically affected. In smaller joints, such as at the fingers, hard bony enlargements, called Heberden's nodes (on the distal interphalangeal joints) or Bouchard's nodes (on the proximal interphalangeal joints), may form, and though they are not necessarily painful, they do limit the movement of the fingers significantly.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.